Achillion Pharmaceuticals, Inc. has received $-0.18 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 6 Financial Advisor in the Stock Trading Firms. Among 6 Analysts, Bottom line EPS Estimate for the current quarter is $-0.19 while the top line estimate is $-0.16 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at -245.83%.
Achillion Pharmaceuticals, Inc. reported better than expected with a surprise EPS of 6.25% or $0.01 during its most recent quarterly earnings. The Actual EPS was $-0.15 compared to the Estimated EPS of $-0.16.
In the last quarter, Achillion Pharmaceuticals, Inc. reported Annual Earnings of $-0.15. Based on the filings, last years Annual Earnings was, $-0.1. In the last Quarter, ACHN reported a surprise Earnings per Share of 6.25% . The consensus estimate for current quarter is $-0.18 and for the current fiscal year, the estimate is $-0.59. For the Next fiscal year, the estimate is $-0.43 based on the consensus.
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) : On Tuesday heightened volatility was witnessed in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) which led to swings in the share price. The stock opened for trading at $4 and hit $4.18 on the upside , eventually ending the session at $4.17, with a gain of 4.51% or 0.18 points. The heightened volatility saw the trading volume jump to 1,694,600 shares. The 52-week high of the share price is $10.06 and the company has a market cap of $570 million. The 52-week low of the share price is at $3.78 .
ACHILLION PHARMACEUTICALS, INC. is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The companys proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease — HIV, hepatitis and resistant bacterial infections. Achillion sees significant competitive advantages in developing anti-infective drugs compared to developing drugs in other therapeutic areas. The emergence of drug resistance seen with current antiviral and antibacterial therapies creates a continuing need for new drugs, providing a large and growing potential business opportunity. In addition, development cycle times tend to be somewhat shorter in infectious disease than other therapeutic areas, and early drug development results tend to be more predictive of longer term results.